Sort
21,453 grants matching “tuberculosis”
International Tuberculosis Clinical Research
$487,751Clifton Barry · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI
Optimizing the impact of Xpert MTB/RIF on treatment outcomes of drug resistant TB
$487,630Annelies Van Rie · Univ Of North Carolina Chapel Hill · R01 · FY2014 · AI
CD4 T Cells in Tuberculosis
$487,620Joanne L. Flynn · University Of Pittsburgh At Pittsburgh · R01 · FY2012 · AI
Orphaned & Separated Children's Assessment Related to their Health & Well-Being
$487,594Paula Karina Alice Braitstein · Indiana University Indianapolis · R01 · FY2011 · HD
BOVINE TUBERCULOSIS IS A CONTAGIOUS DISEASE CAUSED BY A BACTERIA (MYCOBACTERIUM BOVIS) THAT IS TRANSMISSIBLE AMONG ANIMALS AND HUMANS. IT IS ASSOCIATED WITH DEVASTATING CONSEQUENCES TO AGRICULTURE AND PUBLIC HEALTH. IN THE US A WILDLIFE RESERVOIR OF BOVINE TUBERCULOSIS HAS MEANT AN ALARMING INCREASE IN ITS INCIDENCE IN CATTLE IN RECENT YEARS. GLOBAL TRADE AGREEMENTS HAVE ALSO RESULTED IN THE IMPORTATION OF UNTESTED TUBERCULOUS ANIMALS INTO THE US. EXISTING DETECTION STRATEGIES FOR TUBERCULOSIS IN IMPORTED ANIMALS AND LOCAL WILDLIFE--THE TUBERCULIN SKIN TEST (DONE ON THE ANIMAL ITSELF) COUPLED WITH A LAB-BASED INTERFERON-G RELEASE ASSAY--ARE WOEFULLY ILL-EQUIPPED TO TACKLE A PROBLEM OF THIS MAGNITUDE. EXISTING STRATEGIES HAVE NOT BEEN TESTED ON WILDLIFE SPECIMENS ARE LABOR INTENSIVE SUFFER FROM LOW SENSITIVITY AND ARE UNAVAILABLE IN REMOTE FARMING AREAS IN THE US. DEVELOPING COUNTRIES WHERE BOVINE TUBERCULOSIS IS RAMPANT ALSO URGENTLY NEED BETTER WAYS TO QUICKLY IDENTIFY TUBERCULOSIS IN CATTLE.OUR PRELIMINARY STUDIES SHOW THAT CERTAIN CIRCULATING PROTEIN MOLECULES (PEPTIDES) FOUND IN THE BACTERIA CAUSING TUBERCULOSIS (MYCOBACTERIUM TUBERCULOSIS COMPLEX) CAN BE USED AS BIOMARKERS OF SUBCLINICAL TUBERCULOSIS IN CATTLE. WE HAVE DISCOVERED AND VALIDATED 16 M. BOVIS-SPECIFIC PROTEINS IN SERA (BLOOD) OF INFECTED ANIMALS. IN THE PROPOSED STUDIES WE WILL DEVELOP DNA MOLECULES (APTAMERS) SPECIFIC TO 3 OF THE 16 M. BOVIS SPECIFIC PEPTIDES TO DEVELOP A LATERAL FLOW ASSAY SYSTEM FOR ANIMAL-SIDE (PEN-SIDE) DIAGNOSIS OF BOVINE TUBERCULOSIS. TWO AIMS ARE PROPOSED (1) DEVELOP DNA APTAMERS AGAINST 3 BIOMARKERS FOR SUBCLINICAL TUBERCULOSIS (TB) INFECTION AND (2) VALIDATE 3 M. BOVIS SPECIFIC PEPTIDES IN AN APTAMER AND ANTIBODY BASED ANIMAL-SIDE DETECTION SYSTEM. THESE STUDIES ADDRESS A HERETOFORE-UNEXPLORED AREA OF BOVINE TB-SPECIFIC BIOMARKER DISCOVERY AND APTAMERS FOR ANIMAL TUBERCULOSIS. AT COMPLETION WE ANTICIPATE PROVIDING A RAPID LATERAL ANIMAL SIDE DIAGNOSTIC SYSTEM FOR TUBERCULOSIS.
$487,594Michigan State University · · FY2018 · National Institute of Food and Agriculture
In Vitro and In Vivo Pharmacokinetics Core
$487,591Veronique Dartois · Rbhs-New Jersey Medical School · U19 · FY2016 · AI
Broad Institute Comprehensive Screening Center
$487,500Stuart L Schreiber · Broad Institute, Inc. · U54 · FY2012 · HG
Technology and Database for Antimicrobial Identification
$487,187Biolog, Inc. · R43 · FY2005 · AI
Chemical Mycobateriology
$487,056Carolyn R Bertozzi · Stanford University · R37 · FY2021 · AI
Decoding the mechanism of protective and pathological functions of IL-1 during Tuberculosis
$487,002Bibhuti Bhusan Mishra · Albany Medical College · R56 · FY2020 · AI
A Smoking Cessation Trial in HIV-infected patients in South Africa
$486,997Jonathan E Golub · Johns Hopkins University · R01 · FY2014 · DA
Structure and Assembly Dynamics of FtsZ
$486,864Harold P Erickson · Duke University · R01 · FY2012 · GM
Overcoming Genetic Variation in Vaccination
$486,832Samuel M Behar · Univ Of Massachusetts Med Sch Worcester · P01 · FY2019 · AI
Structure and Assembly Dynamics of FtsZ
$486,700Harold P Erickson · Duke University · R01 · FY2010 · GM
Structure and Assembly Dynamics of FtsZ
$486,674Harold P Erickson · Duke University · R01 · FY2011 · GM
In vitro and in vivo efficacy of liposomal ciprofloxacin formulations against Mycobacterium avium and Mycobacterium abscessus
$486,599James D Blanchard · Aradigm Corporation · R44 · FY2017 · AI
ADJUNCT VITAMIN A THERAPY FOR TUBERCULOSIS AND HIV/AIDS
$486,506Johns Hopkins University · R01 · FY2001 · AI
Nanocarriers for transcutaneous delivery of vaccines
$486,465John D Clements · Tulane University Of Louisiana · R01 · FY2008 · EB
Evaluating the Role of L,D-Transpeptidases in Mycobacterial Pathogenesis
$486,440Kimberly Elizabeth Beatty · Oregon Health & Science University · R01 · FY2021 · AI
M. tuberculosis Infection in the Lung
$486,351W. Henry Henry Boom · Case Western Reserve University · R01 · FY2010 · HL
TUBERCULOSIS GENOTYPING AND EVOLUTIONARY CONSORTIUM
$486,313Univ Of Med/Dent Of Nj-Nj Medical School · R01 · FY2004 · AI
Role of ribosome modulating proteins in conferring Mycobacterium abscessus antibiotic resistance
$486,278Pallavi Ghosh · Wadsworth Center · R01 · FY2021 · AI
CRAC Channel Deficiency in Immunity to Infection
$486,036Stefan Feske · New York University School Of Medicine · R01 · FY2017 · AI
CRAC Channel Deficiency in Immunity to Infection
$486,036Stefan Feske · New York University School Of Medicine · R01 · FY2012 · AI
CRAC Channel Deficiency in Immunity to Infection
$486,036Stefan Feske · New York University School Of Medicine · R01 · FY2015 · AI